尿毒清联合厄贝沙坦治疗对老年肾功能不全患者的肾功能和蛋白尿的疗效观察

Niaoduqing combined with irbesartan for elderly patients with renal insufficiency and its influence on renal function and proteinuria

目的探讨尿毒清颗粒联合厄贝沙坦治疗老年肾功能不全的疗效及对患者肾功能和蛋白尿的影响。方法选择2018年1月至2019年12月本院收治的老年慢性肾功能不全患者100例作为研究对象,采用随机数字表法将其分为两组,各50例。参照组采用传统西药治疗,试验组则采用尿毒清颗粒联合厄贝沙坦片治疗。比较两组患者临床疗效、肾功能、24 h尿蛋白排泄率(24 h UAER)以及药物不良反应的发生情况。结果试验组总有效率为94.00%,明显高于参照组80.00%,差异有统计学意义(P<0.05);治疗前,两组患者MAP、BUN、m-Alb、Scr、eGFR、24 h UAER比较,差异均无统计学意义(均P>0.05);治疗后,试验组MAP、BUN、m-Alb、Scr、eGFR、24 h UAER指标分别为(92.41±8.25)mmHg、(6.74±0.65)mmol/L、(68.27±10.68)mg/L、(127.28±81.26)μmol/L、(30.98±8.64)ml/(min·1.73 m2)、(68.46±7.15)mg/24 h,均优于参照组(96.87±6.24)mmHg、(7.62±0.74)mmol/L、(79.42±11.90)mg/L、(236.69±86.47)μmol/L、(27.23±8.26)ml/(min·1.73 m2)、(78.70±7.56)mg/24 h,差异均有统计学意义(均P<0.05);试验组不良反应发生率为8.00%与参照组10.00%比较,差异无统计学意义(P>0.05)。结论尿毒清颗粒联合厄贝沙坦治疗老年肾功能不全疗效显著,可降低患者蛋白尿水平,改善患者的肾功能,值得临床推广和应用。

Objective To explore the effect of Niaoduqing Keli combined with irbesartan in the treatment of elderly renal insufficiency and the effect on renal function and proteinuria.Methods A total of 100 elderly patients with chronic renal insufficiency treated in our hospital from January,2018 to December,2019 were selected as research objects.They were divided into a test group and a reference group by the random number table method,with 48 cases in each group.The reference group were treated with traditional western medicine,and the experimental group with Niaoduqing Keli and irbesartan tablets.The clinical efficacies,renal function,24-hour urinary albumin excretion rates(24-hour UAER),and the incidences of adverse drug reactions were compared between the two groups.Results The total effective rate was 94.00%in the experimental group,and was 80.00%in the reference group,with a statistical difference(P<0.05).Before the treatment,there were no statistical differences in MAP,BUN,m-Alb,Scr,eGFR,and 24 h UAER between the two groups(all P>0.05).After the treatment,the MAP,BUN,m-Alb,Scr,eGFR,and 24h UAER were better in the test group than in the reference group[(92.41±8.25)mmHg vs.(96.87±6.24)mmHg,(6.74±0.65)mmol/L vs.(7.62±0.74)mmol/L,(68.27±10.68)mg/L vs.(79.42±11.90)mg/L,(127.28±81.26)μmol/L vs.(236.69±86.47)μmol/L,(30.98±8.64)ml/(min·1.73 m2)vs.(27.23±8.26)ml/(min·1.73 m2),and(68.46±7.15)mg/24 h vs.(78.70±7.56)mg/24 h;all P<0.05].The incidence of adverse reactions was 8.00%in the test group,and was 10.00%in the reference group,with no statistical difference(P>0.05).Conclusion Niaoduqing Keli combined with irbesartan in the treatment of elderly patients with renal insufficiency is effective,and can reduce their proteinuria and improve their renal function,so it is worthy of clinical promotion and application.